Onconetix (ONCO) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
23 Oct, 2026Executive summary
An additional $500,000 was advanced to Realbotix on Oct. 22, 2026, under a grid promissory note providing for loans of up to $5.0 million.
After the advance, principal outstanding under the note totaled $3.0 million; its terms remained unchanged.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Onconetix
- Five proposals include approval for up to 154.9 million Series F conversion shares.ONCO
Proxy filing - Shareholders to vote on Series F conversion, reverse stock split, and adjournment authority.ONCOProxy filing
- Bridge financing supports a pending all-stock acquisition, subject to shareholder and regulatory approval.ONCOProxy filing
- Registering 100M shares for resale, company faces dilution, cash constraints, and execution risks.ONCORegistration filing
- Revenue fell sharply, losses persisted, and liquidity risks remain despite new financings.ONCOQ2 2026
- Registering 100M shares for resale, company faces dilution, financing, and operational risks.ONCORegistration filing
- Equity line registration enables up to 100M new shares, posing major dilution and funding risks.ONCORegistration filing
- Significant losses, cash constraints, and urgent funding needs persist despite clinical progress.ONCOQ1 2026
- Registration enables resale of 25M shares by Keystone Capital Partners, LLC.ONCORegistration filing